Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10748243 | 0.86 | HSD17B10 (0.56) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL600868 | 0.85 | HSD17B10 (0.60) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL17125223 | 0.81 | HSD17B10 (0.60) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL1030342 | 0.81 | ALDH1A1 (0.60) | HSD17B10KMT2AALDH1A1TDP1LMNA | |
| SCHEMBL29744802 | 0.81 | ALDH1A1 (0.60) | HSD17B10KMT2AALDH1A1TDP1LMNA | |
| SCHEMBL16954413 | 0.79 | HSD17B10 (0.56) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL19862412 | 0.79 | HSD17B10 (0.56) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL18048843 | 0.78 | HSD17B10 (0.51) | HSD17B10VCAM1KMT2AALDH1A1LMNA | |
| SCHEMBL16957943 | 0.78 | HSD17B10 (0.51) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL18048536 | 0.78 | PTPRC (0.44) | HSD17B10ALDH1A1TDP1LMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404231-B2 | Method for preparing trifluoromethyl aromatic compound | JINGDEZHEN FUSHINE LIFE TECHNOLOGY CO., LTD. (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20250257028-A1 | Method for Preparing Trifluoromethyl Aromatic Compound | JINGDEZHEN FUSHINE LIFE TECHNOLOGY CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| CN-117964490-B | Preparation method of trifluoromethyl aromatic compound | 景德镇富祥生命科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-117964490-A | Preparation method of trifluoromethyl aromatic compound | 景德镇富祥生命科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-19 | — | — | US | disclosed |
| CN-1312151-C | (imidazol-1-yl-methyl)-pyridazine as NMDA receptor blocker | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | CN | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| CN-1653062-A | (imidazol-1-yl-methyl)-pyridazine as NMDA receptor blocker | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | CN | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257028-A1 | Method for Preparing Trifluoromethyl Aromatic Compound | PAH, KCNH3, RCC1 | HSD17B10 3239/4885VCAM1 4277/4885KMT2A 409/4885 |
| US-12404231-B2 | Method for preparing trifluoromethyl aromatic compound | PAH, KCNH3, RCC1 | HSD17B10 3239/4885VCAM1 4277/4885KMT2A 409/4885 |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | HSD17B10 3548/4885VCAM1 2729/4885KMT2A 966/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | HSD17B10 1076/4885VCAM1 3075/4885KMT2A 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.